Prophylaxis Against High-Dose Cytarabine Ocular Toxicity
Prednisolone acetate 1% eye drops are instilled prophylactically before high-dose cytarabine consolidation to prevent corneal toxicity and hemorrhagic conjunctivitis, which are well-established complications of this chemotherapy regimen.
Mechanism and Rationale
High-dose cytarabine (typically ≥1-3 g/m² per dose) used in AML consolidation therapy causes direct corneal epithelial damage and conjunctival inflammation. Without prophylaxis, patients develop:
- Severe ocular pain, photophobia, and tearing (median onset 6.5 days after starting therapy)
- Hemorrhagic conjunctivitis
- Corneal epithelial toxicity
- Symptoms lasting approximately one week
Evidence Base
The NCCN guidelines explicitly recommend "saline or steroid eye drops to both eyes 4 times daily for all patients undergoing high-dose cytarabine therapy until 24 hours post completion of cytarabine" 1. This is a Category 2A recommendation applicable to all patients receiving high-dose cytarabine during consolidation.
A randomized, double-masked trial demonstrated that topical corticosteroid prophylaxis (1% prednisolone phosphate) significantly reduced both the intensity and duration of corneal toxicity symptoms compared to placebo (P < 0.0005) in 10 of 11 patients 2. The FDA drug label for cytarabine specifically warns that experimental high-dose regimens cause "reversible corneal toxicity and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop" 3.
Clinical Implementation
Timing and dosing:
- Start prednisolone acetate 1% eye drops 12 hours before the first cytarabine dose
- Continue four times daily throughout the entire cytarabine treatment course
- Extend until 24 hours after the final cytarabine dose
Alternative: Saline eye drops can be used, though steroid drops provide superior protection based on the available evidence 2.
Important Context
This prophylaxis is specifically indicated for high-dose cytarabine regimens (≥1 g/m² per dose), which are standard for AML consolidation in younger patients and those with favorable or intermediate-risk disease 4. The recent EORTC-GIMEMA AML-12 trial showed increased conjunctivitis rates with high-dose cytarabine (12.4%) versus standard-dose (0.5%), reinforcing the need for prophylaxis 4.
Common pitfall: Failing to start eye drops prophylactically before chemotherapy initiation. Once corneal toxicity develops, it causes significant morbidity and may require treatment interruption. Prevention is far more effective than treatment.